Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

@article{Mass2005EvaluationOC,
  title={Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.},
  author={Robert D. Mass and Michael F Press and Steven Anderson and Melody A. Cobleigh and Charles Le. Vogel and No{\"e}l Dybdal and Grazyna Leiberman and Dennis J Slamon},
  journal={Clinical breast cancer},
  year={2005},
  volume={6 3},
  pages={
          240-6
        }
}
BACKGROUND We evaluated the influence of HER2 gene amplification, as determined by fluorescence in situ hybridization (FISH), on clinical outcomes (objective response rates, time to disease progression, and overall survival time) in women with metastatic breast cancer treated with trastuzumab in 3 clinical trials. Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay. MATERIALS AND METHODS Specimens with a HER2:CEP17 ratio of > or = 2:0 were considered… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 163 CITATIONS, ESTIMATED 49% COVERAGE

Nano-biosensor for highly sensitive detection of HER2 positive breast cancer.

  • Biosensors & bioelectronics
  • 2018
VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society

  • Journal of Cancer Research and Clinical Oncology
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2004
2019

CITATION STATISTICS

  • 8 Highly Influenced Citations

  • Averaged 8 Citations per year from 2017 through 2019